A recent review published by Elsevier highlights advances in liquid biopsy particularly circulating tumor DNA (ctDNA) profiling, a valuable analyte that helps explore various aspects for cancer care. The review summarizes clinical benefits of ctDNA CGP and future directions for liquid biopsy CGP(Comprehensive genome profiling).
Outlining the clinical benefits of Liquid biopsy(LB):
Alternative to tissue biopsy: LB profiling is established for therapy selection in advanced cancers when tissue biopsy seems too risky or unavailable.
Faster treatment - High specificity detects actionable variants at low frequencies with a high positive predictive value, avoiding ineffective therapies.
Guides targeted therapies - LB can detect resistance alterations not found in tissue biopsies
Future of LB for ctDNA Analysis:
Clonal hematopoiesis variants in ctDNA predict myeloid neoplasms, transplant outcomes, and immunotherapy response.
Guides early treatment and precision therapy for pre-metastatic and hematological malignancies.
Can ctDNA Profiling Predict Treatment Outcomes?
Provides prognostic value and measures tumor burden in various cancers.
The ongoing PROTRACT study in prostate cancer explores ctDNA levels to guide treatment decisions.
Longitudinal monitoring of ctDNA tracks response to precision therapies and chemotherapy.
At Kyvor Genomics, our CANLYTx LB (DNA Whole Exome) test uses NGS to analyze 20,000 genes, focusing on 1800+ cancer-related genes. Tailored for advanced metastatic breast, colon, and gynecological cancers, this multigene liquid CGP-based assay offers diverse diagnostic and treatment opportunities. This indicates a promising future for patient-centered diagnostics in clinical care and research.
The War against Cancer can be Won